Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Biochip for the diagnosis of Familial Hypercholesterolemia

10.02.2004


Hypercholesterolemia patients now have a new method of diagnosis that enables them to know for sure if they are suffering from Familial Hypercholesteloremia (FH) or not. The new tool, known as Lipochip, is the first biochip for the diagnosis of Familial Hypercholesteloremia (a pathology that affects some 100,000 persons in Spain).



The majority of those currently suffering from FH are not diagnosed as such. It is calculated that less than 30% of them have received a correct diagnosis with the majority receiving inadequate or inappropriate treatment. Moreover, when the illness is diagnosed, it is often too late as the patient a premature cardiovascular event which may be life-threatening.

Lipochip enables the early diagnosis of a large number of patients in a short space of time. In this way, cardiovascular illnesses can be prevented, these pathologies appearing in more than half of the patients affected by FH before 55 years of age. Amongst those between 20 and 39 years of age who suffer from Familial Hypercholesterolemia, mortality due to a coronary pathology is 100 times greater than amongst those without FH.


The importance of early diagnosis of FH with Lipochip lies in this high incidence of level of premature cardiovascular illnesses amongst FH patients. Without the correct diagnosis and treatment, many patients die between 35 and 65 years of age, and seven out of ten will suffer myocardiac attack before their sixtieth birthday. However, with early diagnosis and treatment, the survival rate and quality of life of patients improves, as these coronary events are greatly diminished. This also reduces hospital costs as there are less cardiovascular events amongst patients being suitably diagnosed and treated.

Early detection

Another important aspect, that can only be covered by the use of Lipochip, is the detection of the illness amongst young people who do not have symptoms but who, not being diagnosed early or receiving appropriate treatment, are subject to having an unexpected cardiovascular events. Up to now, the clinical diagnosis of FH has been based on typical clinical signs, on analytical data and on family history of the patient.

Thanks to the use of Lipochip, the illness can be diagnosed with complete reliability, i.e. knowing if the patient is a carrier of one of the mutations responsible for FH, using a small blood sample and in a matter of just a few days. Even in those patients that have a definite clinical diagnosis, the detection of the mutation may have prognostic value, given that some studies back up the hypothesis that the type of mutation may also have an influence on the response to pharmaceutical drugs, and so with the type of mutation determining the treatment.

Lipochip enables the carrying out of a genetic diagnosis of Familial Hypercholesterolemia, and considered to be of the greatest reliability. In this way, the appearance of false positives and false negatives are eliminated, which have arisen up to now using the diagnostic table of MedPed (the international programme of the World Health Organisation). The WHO, by means of this programme, recommended the development of techniques capable of detecting mutations in the LDL receptor gene in order to provide a reliable and early diagnosis of Familial Hypercholesterolemia. The mutations in this gene are the cause FH.

The principle of Lipochip is the capacity of DNA to recognise its complementary sequence.
Basically, it consists of a chemically modified glass surface onto which a large number of genic sequences complementary to each of the mutations have been deposited. To this surface the patient’s sample, marked with a fluorescent molecule, is added. Subsequent illumination with laser enables the identification of which of the points the patient’s blood sample has bonded to with greatest intensity. In this way specific discrimination between a normal patient and one suffering from Familial Hypercholesterolemia is established.

The novelty of this diagnostic tool is that it enables the analysis of thousands of sequences in a differentiated, rapid and reliable manner, unlike the traditional techniques of the independent analysis of each sequence in question, which can take months.

Lipochip has been designed and developed by the Progrenika-Medplant technological support group, based on knowledge provided by Familial Hypercholesterolemia Foundation and the Department of Biochemistry at the University of Zaragoza.


Contact :
Laureano Simón
Progenika S.A.
lsimon@progenika.com
(+34) 944064525

Garazi Andonegi | Basque research
Further information:
http://www.basqueresearch.com/berria_irakurri.asp?Gelaxka=1_1&Berri_Kod=408&hizk=I
http://www.progenika.com

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>